Obalon Announces Clinical Data Set to be Featured During the 36th ASMBS Annual Meeting at Obesity Week 2019
November 05 2019 - 4:15AM
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions
company with the first and only FDA-approved swallowable,
gas-filled intragastric balloon system for the treatment of
obesity, announces that clinical data for the Obalon Balloon
System used to treat 222 patients at the Hamad Medical Corporation,
a leading hospital provider in the Middle East, will be featured in
a poster presentation at the American Society for Metabolic and
Bariatric Surgery (ASMBS) Annual Meeting at Obesity Week 2019,
being held November 3-7, 2019 in Las Vegas, Nevada.
The poster titled Hamad Medical Corporation (Qatar)
National Payor Program Experience with a Swallowable, Gas-filled
Intragastric Balloon System was co-authored by Mohammed Rizwan, MD,
Ahmed Mohamed Elnagar, MD, Moataz Bashah, MD and Helmuth Billy,
MD.
The commercial clinical data set includes 222
consecutive patients that initiated treatment with the Obalon
six-month balloon system from February 2018 to October 2018 and met
the analysis inclusion criteria, including a starting BMI greater
than or equal to 27 kg/m2. Average weight loss for patients
meeting the inclusion criteria and receiving three balloon therapy
was 24.7 pounds, resulting in a 11.9% reduction in total body
weight. Adverse Events were reported by 31% of the patients and
there were no (0%) Serious Adverse Events reported.
“We have been very pleased with our experience and
patient outcomes with the swallowable, gas-filled Obalon Balloon,”
said Dr. Rizwan. “We are presenting very strong clinical data on
the Obalon Balloon at Obesity Week showing 24.7 pounds of average
weight loss for patients receiving three balloons with no serious
adverse events reported.”
“This new data set adds to the body of scientific
evidence supporting the Obalon Balloon System as an effective and
safe tool for promoting weight loss,” said Amy VandenBerg, Chief
Clinical, Quality and Regulatory Officer of Obalon. “Data continues
to be presented in scientific forums as they become available to
augment our efficacy and safety database, which includes the
results from our pivotal clinical trial that supported FDA
approval, as well as the data from our commercial registry in the
United States, which demonstrated successful results in over 1,300
individuals with obesity. As more patients and physicians become
familiar with our novel weight loss solution, we believe the Obalon
Balloon System has potential to significantly impact the obesity
epidemic.”
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based
company focused on developing and commercializing novel
technologies for weight loss. For more information, please
visit www.obalon.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Obalon Therapeutics, they are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor of the Private Securities Reform Act of 1995. Such
forward-looking statements involve substantial risks and
uncertainties that could cause Obalon Therapeutics' future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Obalon
Therapeutics undertakes no obligation to update or revise any
forward-looking statements. For a description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Obalon Therapeutics' business in general, please refer
to Obalon Therapeutics’ annual report on Form 10-K filed with the
Securities and Exchange Commission on February 22, 2019, its
quarterly report on Form 10-Q filed with the Securities and
Exchange Commission on July 24, 2019, and its future periodic
reports filed with the Securities and Exchange Commission.
For Obalon Therapeutics, Inc.
Investor Contact: William Plovanic President and
Chief Executive Officer Obalon Therapeutics, Inc. Office: +1 760
607 5103 wplovanic@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2024 to May 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From May 2023 to May 2024